Citations

Abstract Background Research on gender and ethnic differences in white matter tracts yields mixed results. Although men show larger global corpus callosum (CC) in absolute values, women have demonstrated larger splenium and isthmus. Additionally, men have shown greater white matter and fractional anisotropy (FA) in multiple regions than women. This study investigates sex and ethnic differences in the corpus callosum and transcallosal white matter tissue microstructure of older individuals with normal cognition and memory disorders. Method 191 participants (Female n = 120; Hispanics n = 115; Non‐Hispanics n = 76; Age mean = 71.07; SD = 7.75) were included in the sample from the 1Florida ADRC with cognitively normal ( n = 75), MCI ( n = 88), and dementia ( n = 28) diagnoses. Corpus callosum volumes were collected using a Siemens Skyra 3T MRI scanner and were divided into anterior, mid‐anterior, central, mid‐posterior, and posterior regions. Also, MRI‐based free water diffusion tensor imaging (FW‐DTI) measured FW‐corrected FA (fwcFA) to assess and compare the integrity of transcallosal tract templates (TCATT) across motor, temporal, parietal, and occipital regions across males and females and ethnic groups. Result Univariate ANCOVAs controlling for age and clinical diagnosis were performed; females had larger normalized CC volumes in the posterior, F (1, 184) = 8.92, p = .003, η p 2 = .046, mid‐anterior, F (1,184)= 5.68, p = .018, η p 2 = .030, and anterior, F (1,184)= 14.54, p < .001, η p 2 = .073, regions, which all survived FDR corrections, with no ethnic differences observed. For transcallosal tracts, females had higher fwcFA in the inferior temporal gyrus, η p 2 Hispanics had higher fwcFA in the premotor cortex, η p 2 η p 2 Conclusion Sex and ethnicity influence white matter changes during aging independently of age and cognitive diagnosis. However, the effect explained by these demographic variables was very small, suggesting the influence of additional factors.

Abstract Background Tau PET measures are inherently continuous and applying dichotomized thresholds introduces conceptual and analytical idiosyncrasies. Understanding the limitations in the transition from tau‐negative to tau‐positive classifications is crucial for the effective use of these thresholds. This study aims to determine the confidence levels of tau PET thresholds of abnormality for different tau PET tracers by characterizing their “gray zone” using the universal tau PET scale (Uniτ, www.unitau.app ). Method We evaluated 485 individuals across the aging and AD spectrum from the HEAD study, with head‐to‐head scans for MK6240 and Flortaucipir. Uniτ estimates were derived from the Meta‐Temporal ROI. Tau positivity (T+) was defined as Uniτ values exceeding the mean plus 3 SD of individuals younger than 28 years ( n = 24). Two physicians independently performed a visual assessment of tau positivity for each tracer, with agreement indicating clear tau pathology (TVR+). Logistic regression was used to estimate the probability of TVR+ across Uniτ values for each tracer ( n = 189, CU elderly Aβ‐ and CI Aβ+). Individuals were classified as negative, positive, or within a “gray zone” between the most liberal T+ threshold and varying TVR+ probability thresholds (50%, 75%, 90%, 95%, and 99%). Result The Uniτ gray zone, defined as a function of TVR+ probabilities, demonstrated consistency between the two tracers, with differences observed only in the decimal range. The most liberal Uniτ threshold for T+ was 11.0 for both MK6240 and Flortaucipir, closely matching the 50% TVR+ probability threshold (11.1 for MK6240 and 11.7 for Flortaucipir). Higher TVR+ probabilities corresponded to increased Uniτ values with MK6240 and Flortaucipir showing near‐identical values between the tracers: 14.2 and 14.8 for 75%, 17.3 and 17.9 for 90%, 19.4 and 19.9 for 95%, and 24.1 and 24.6 for 99%, respectively (Figure 1). In total, 26 participants fell within the gray zone for MK6240, compared to 47 participants for Flortaucipir. Conclusion These findings highlight the potential of Uniτ to provide a standardized approach for assessing tau positivity across tracers. By combining quantitative Uniτ measures with visual assessments, we enhance the understanding of tau positivity certainty, particularly in the transition between negative and positive classifications.

Abstract Background Sex, education and race/ethnicity are all associated with risk of Alzheimer's disease dementia. Here, we assess the effects of self‐reported sex, educational attainment and race/ethnicity on amyloid‐positivity, and tau‐PET‐positivity in 12,048 (7,394 cognitively unimpaired [CU], 2,177 MCI, and 2,477 dementia) individuals from 42 cohorts worldwide. Method Logistic generalized estimating equations were used to estimate frequency of amyloid‐positivity (using cohort‐specific thresholds for amyloid‐PET [84%] or CSF) and tau‐PET‐positivity (cohort‐specific thresholds of 2SD above mean temporal uptake in amyloid‐negative controls). We assessed: i) sex and APOEε4 ( N = 10,098) associations, to complement earlier findings of a higher frequency of tau‐positivity in females, ii) effects of lower/higher education ( N = 10,970; cohort‐specific median‐split), and iii) effects of race/ethnicity (non‐Hispanic White [hereafter: White], N = 4880; Asian, N = 116; Black or African‐American [hereafter: Black], N = 353; Hispanic, N = 356, only from Northern‐American cohorts). Outcomes were frequency of amyloid‐positivity in CU individuals only, and tau‐PET‐positivity in both amyloid‐positive (AB+) CU and cognitively impaired (CI, i.e. MCI and dementia) individuals. Interaction effects on the relationship between age and amyloid/tau‐positivity were assessed and only retained in the models when significant. Result Female sex was associated with an APOEε4 ‐independent increased frequency of amyloid‐positivity (β=0.51[0.22], p = 0.02) in CU and increase of tau‐positivity in both AB+CU (β=0.27[0.08]) and AB+CI (β=0.37[0.08], both p <0.01). Remarkably, tau‐positivity frequencies of female APOEε4 non‐carriers were equivalent to male APOEε4 carriers in AB+CI (Figure 1). No significant sex* APOE interactions were observed. In CU, higher education was associated with lower amyloid‐positivity frequency (β=‐0.12[0.05], p = 0.02). In contrast, among AB+CU, there was an age*education interaction effect that indicated more pronounced age effects on tau‐positivity in individuals with higher education (age*education:β interaction =0.03[0.01], p <0.01). There were no education effects in AB+CI (Figure 2). In CU, an age*race/ethnicity interaction effect was observed across all non‐White groups compared to White (Hispanic:β interaction =‐0.05[0.01], p <0.01; Black:‐0.04[0.01], p <0.01; Asian:‐0.02[0.01], p = 0.04). This suggests that the impact of age on amyloid‐positivity was less pronounced in non‐White groups. Furthermore, in AB+CI, Hispanic ethnicity was related to higher tau‐positivity frequency than White (β=0.51[0.22], p = 0.02; Figure 3). Conclusion In this multi‐center initiative comprised of clinical and community‐based cohorts, we observed that self‐reported sex, educational attainment and race/ethnicity were related to positivity‐frequencies of Alzheimer's disease pathology.

Radiologists are uniquely positioned to play a critical role in the detection, surveillance, and characterization of hereditary abdominal cancer syndromes.

The interpretation of gynecologic pelvic MRI benefits from tailored MRI protocols, radiologists' knowledge of normal female pelvic anatomy, and a step-by-step approach focusing on lesion origin, lesion tissue composition, and solid tissue morphology, with findings presented in a structured report.

Abstract Background Studies suggest that sex influences the deposition of tau in the human brain and impacts on the relationship of tau with AD‐related outcomes. The aim of this study is to evaluate the extent to which sex influences PET‐Tau related outcomes and whether this effect is related to specific tau PET tracers. Method We assessed 456 participants from the HEAD study (mean age = 66.07 ± 13.05). All individuals had available Tau‐PET with Flortaucipir and MK6240, Aβ‐PET and a subset had plasma p ‐Tau 217 ( n = 352). We conducted a linear regression analysis between sex and PET Tau to evaluate the direct influence of sex on PET Tau SUVR. Next, we assessed whether sex affected the relationship between Tau PET (in BRAAK I‐II, III‐IV, V‐VI regions) and Aβ‐PET or plasma p ‐Tau 217 by adding an interaction term in the associations. All analyses were corrected by age, clinical classification, and amyloid burden. Result No significant differences were observed between male and female SUVR levels in either Flortaucipir and MK6240 tracers (Figure 1). However, when assessing the relationship between Aβ‐PET and Tau, a statistically significant interaction with sex was seen between MK6240 in BRAAK III‐IV (β = 0.160, p = 0.020 ; Figure 2) and BRAAK V‐VI regions (β = 0.196, p = 0.008; Figure 2), with women having a stronger association. Furthermore, we found an interaction between sex and p ‐tau217 on Tau PET SUVR in BRAAK regions I‐II using MK6240 or Flortaucipir (β = ‐0.184, p = 0.014; β = ‐0.266, p = 0.002; Figure 3) indicating that women present a weaker relationship between p ‐tau217 and Tau PET. Conclusion Our results did not show any differences between men and women in Tau‐PET SUVR uptake across tau tracers. However, we found that sex affected how Aβ‐PET and plasma p ‐tau217 were associated with Tau‐PET uptake. Further studies are needed to elucidate the underpinnings of the link between sex and the association between these biomarkers.

Abstract INTRODUCTION We standardized positron emission tomography (PET) data across multiple cohorts and tracers to characterize the frequency of amyloid and tau PET severity along the clinical continuum. METHODS Clinical stage was defined using cohort‐specific criteria and included cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia. Amyloid severity was staged using Centiloids (CL). Tau severity was staged using a hierarchical Braak‐based schema. The cumulative probabilities of PET‐based stages were estimated using ordinal logistic regressions. RESULTS Among 10,396 individuals (mean [standard deviation] age: 71.9 [7.1] years), amyloid levels ≥ 25 CL increased with age among CU and MCI, while amyloid levels ≥ 100 CL were most common in dementia. In 3295 with tau PET, tau severity increased with amyloid and clinical stage and showed complex associations with age. Within each clinical stage, the full spectrum of amyloid and tau PET severity was observed. DISCUSSION PET‐based staging revealed heterogeneous amyloid and tau burden along the clinical continuum. Highlights PET‐based staging is feasible across multiple cohorts and PET tracers. There is heterogeneity in amyloid and tau severity across the clinical spectrum. The frequency of amyloid and tau PET severity increased with clinical severity. The likelihood of tau PET severity differed by age, amyloid, and clinical severity.

Abstract INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.